Durable antitumor responses to CD47 blockade require adaptive immune stimulation

Therapeutic antitumor antibodies treat cancer by mobilizing both innate and adaptive immunity. CD47 is an antiphagocytic ligand exploited by tumor cells to blunt antibody effector functions by transmitting an inhibitory signal through its receptor signal regulatory protein alpha (SIRPα). Interferenc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Proceedings of the National Academy of Sciences - PNAS 2016-05, Vol.113 (19), p.E2646-E2654
Hauptverfasser:	Sockolosky, Jonathan T., Dougan, Michael, Ingram, Jessica R., Ho, Chia Chi M., Kauke, Monique J., Almo, Steven C., Ploegh, Hidde L., Garcia, K. Christopher
Format:	Artikel
Sprache:	eng
Schlagworte:	Adaptive Immunity - drug effects Adaptive Immunity - immunology Animals Antibodies, Monoclonal, Murine-Derived - administration & dosage Antibodies, Monoclonal, Murine-Derived - immunology Antineoplastic Agents - administration & dosage Antineoplastic Agents - immunology Biological Sciences Cancer Cancer Vaccines - administration & dosage Cancer Vaccines - immunology CD47 Antigen - drug effects CD47 Antigen - immunology Female Immune system Immunization - methods Ligands Male Mice Mice, Inbred C57BL Molecular Targeted Therapy - methods Monoclonal antibodies Neoplasms, Experimental - immunology Neoplasms, Experimental - pathology Neoplasms, Experimental - therapy PNAS Plus Proteins Rodents Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!